Multiplex Assay Kit for Noggin (NOG) ,etc. by FLIA (Flow Luminescence Immunoassay) 
SYM1; SYNS1; Synostoses(Multiple)Syndrome 1; Symphalangism 1(Proximal)
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 449.00 US$ 467.00 US$ 492.00 US$ 527.00 US$ 562.00 US$ 613.00 US$ 691.00 US$ 864.00
- Quantity
Overview
Properties
- Product No.LMC130Mi
- Organism SpeciesHomo sapiens (Human), Mus musculus (Mouse), Rattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transductionImmune moleculeNeuro scienceBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Noggin (NOG) and the recovery rates were calculated by comparing the measured value to the expected amount of Noggin (NOG) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 81-92 | 88 |
| EDTA plasma(n=5) | 91-99 | 94 |
| heparin plasma(n=5) | 88-105 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Noggin (NOG) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Noggin (NOG) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Noggin (NOG) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-90% | 91-101% | 92-104% | 81-101% |
| EDTA plasma(n=5) | 79-101% | 96-103% | 79-104% | 80-88% |
| heparin plasma(n=5) | 81-90% | 94-101% | 79-95% | 96-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:NOG) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Noggin (NOG) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Noggin (NOG) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Noggin (NOG) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Noggin (NOG) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Imbalance between BMP2 and Noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitisPubMed: 26413886
- Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing SpondylitisPubmed:26413886
- Oxygen-glucose deprivation preconditioning protects neurons against oxygen-glucose deprivation/reperfusion induced injury via bone morphogenetic protein-7 mediated ERK, p38 and Smad signalling pathways.Pubmed:26385023
- The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells.pubmed:28266688
- mbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal OsteogenicDifferentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis.pubmed:26413886
- The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.pubmed:28981962
- Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesispubmed:29167826
- Low‐intensity pulsed ultrasound promotes bone morphogenic protein 9‐induced osteogenesis and suppresses inhibitory effects of inflammatory cytokines on cellular …Pubmed: 31006911
- Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatmentPubmed: 32160825
- Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat Epigastric Free Flap ModelPubmed: 31995818
- Slow diffusion on the monolayer culture enhances auto/paracrine effects of Noggin in differentiation of human iPS cells induced by BMPPubmed:35005256